Results of parallel multivariate analysis of ZAP70 status, CD38 status, IgVH status, FISH status for 17p and 11q combined or alternatively TP53 exon 2-10 mutations, Rai stage, and SNP 6.0 array–based lesions treated as a continuous variable on OS in previously untreated patients with CLL (n = 187)
| Variable . | n/N . | HR . | CI . | P . | Variable . | n/N . | HR . | CI . | P . |
|---|---|---|---|---|---|---|---|---|---|
| SNP 6.0 array genomic lesions (continuous variable)* | N/A | 1.13 | 1.03-1.25 | .01 | SNP 6.0 array genomic lesions (continuous variable)* | N/A | 1.16 | 1.06-1.26 | < 0.01 |
| Del17p or del11q present vs not | 28/159 | 2 | 0.6-7.2 | .28 | TP53 exon 2-10 mutated vs not | 22/165 | 3 | 1.2-8.1 | .03 |
| Rai stage I-IV vs 0 | 90/97 | 0.9 | 0.4-2.4 | .85 | Rai stage I-IV vs 0 | 90/97 | 0.9 | 0.4-2.3 | .79 |
| ZAP70 ≥ 20% vs < 20% | 80/107 | 0.7 | 0.2-1.9 | .42 | ZAP70 ≥ 20% vs < 20% | 80/107 | 0.7 | 0.2-1.9 | .45 |
| IgVH UM vs M | 79/108 | 1.6 | 0.6-4.8 | .37 | IgVH UM vs M | 79/108 | 1.7 | 0.6-4.9 | .35 |
| CD38 ≥ 30% vs < 30% | 45/142 | 0.5 | 0.1-1.8 | .26 | CD38 ≥ 30% vs < 30% | 45/142 | 0.5 | 0.1-1.8 | .28 |
| Square root of SNP 6.0 array genomic lesions (continuous variable)† | N/A | 2.3 | 1.4-3.7 | < .01 | Square root of SNP 6.0 array genomic lesions (continuous variable)† | N/A | 2.3 | 1.5-3.5 | < .01 |
| Del17p or del11q present vs not | 28/159 | 1.2 | 0.3-4.7 | .77 | TP53 exon 2-10 mutated vs not | 22/165 | 2.1 | 0.8-5.9 | .13 |
| Rai stage I-IV vs 0 | 90/97 | 0.8 | 0.3-2.2 | .71 | Rai stage I-IV vs 0 | 90/97 | 0.9 | 0.3-2.2 | .76 |
| ZAP70 ≥ 20% vs < 20% | 80/107 | 0.7 | 0.2-2 | .5 | ZAP70 ≥ 20% vs < 20% | 80/107 | 0.7 | 0.3-2 | .48 |
| IgVH UM vs M | 79/108 | 1.6 | 0.5-4.7 | .4 | IgVH UM vs M | 79/108 | 1.5 | 0.5-4.6 | .43 |
| CD38 ≥ 30% vs < 30% | 45/142 | 0.5 | 0.1-1.8 | .28 | CD38 ≥ 30% vs < 30% | 45/142 | 0.5 | 0.1-1.7 | .24 |
| Variable . | n/N . | HR . | CI . | P . | Variable . | n/N . | HR . | CI . | P . |
|---|---|---|---|---|---|---|---|---|---|
| SNP 6.0 array genomic lesions (continuous variable)* | N/A | 1.13 | 1.03-1.25 | .01 | SNP 6.0 array genomic lesions (continuous variable)* | N/A | 1.16 | 1.06-1.26 | < 0.01 |
| Del17p or del11q present vs not | 28/159 | 2 | 0.6-7.2 | .28 | TP53 exon 2-10 mutated vs not | 22/165 | 3 | 1.2-8.1 | .03 |
| Rai stage I-IV vs 0 | 90/97 | 0.9 | 0.4-2.4 | .85 | Rai stage I-IV vs 0 | 90/97 | 0.9 | 0.4-2.3 | .79 |
| ZAP70 ≥ 20% vs < 20% | 80/107 | 0.7 | 0.2-1.9 | .42 | ZAP70 ≥ 20% vs < 20% | 80/107 | 0.7 | 0.2-1.9 | .45 |
| IgVH UM vs M | 79/108 | 1.6 | 0.6-4.8 | .37 | IgVH UM vs M | 79/108 | 1.7 | 0.6-4.9 | .35 |
| CD38 ≥ 30% vs < 30% | 45/142 | 0.5 | 0.1-1.8 | .26 | CD38 ≥ 30% vs < 30% | 45/142 | 0.5 | 0.1-1.8 | .28 |
| Square root of SNP 6.0 array genomic lesions (continuous variable)† | N/A | 2.3 | 1.4-3.7 | < .01 | Square root of SNP 6.0 array genomic lesions (continuous variable)† | N/A | 2.3 | 1.5-3.5 | < .01 |
| Del17p or del11q present vs not | 28/159 | 1.2 | 0.3-4.7 | .77 | TP53 exon 2-10 mutated vs not | 22/165 | 2.1 | 0.8-5.9 | .13 |
| Rai stage I-IV vs 0 | 90/97 | 0.8 | 0.3-2.2 | .71 | Rai stage I-IV vs 0 | 90/97 | 0.9 | 0.3-2.2 | .76 |
| ZAP70 ≥ 20% vs < 20% | 80/107 | 0.7 | 0.2-2 | .5 | ZAP70 ≥ 20% vs < 20% | 80/107 | 0.7 | 0.3-2 | .48 |
| IgVH UM vs M | 79/108 | 1.6 | 0.5-4.7 | .4 | IgVH UM vs M | 79/108 | 1.5 | 0.5-4.6 | .43 |
| CD38 ≥ 30% vs < 30% | 45/142 | 0.5 | 0.1-1.8 | .28 | CD38 ≥ 30% vs < 30% | 45/142 | 0.5 | 0.1-1.7 | .24 |
Continuous variable was displayed either as a linear variable or as the square root of the number of acquired lesions; see supplemental Methods. The hazard ratio for SNP 6.0 array–based lesions is multiplicative for any unit increase.
Multiplicative hazard for any unit increase.
Multiplicative hazard for any unit increase.